2. Altundag K, Dizdar O, Ozsaran Z, Ozkok S, Saip P, Eralp Y, Komurcu S, Kuzhan O, Ozguroglu M, Karahoca M. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain. Onkologie. 2012;35(5):254-8. doi: 10.1159/000338369. Epub 2012 Apr 24. PubMed PMID: 22868504.
3. Arslan N, Tuncel M, Kuzhan O, Alagoz E, Budakoglu B, Ozet A, Ozguven MA. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011 Jul;25(6):406-13. doi: 10.1007/s12149-011-0478-y. Epub 2011 Mar 17. PubMed PMID: 21409347.
4. Ozturk M, Ozler M, Kurt YG, Ozturk B, Uysal B, Ersoz N, Yasar M, Demirbas S, Kurt B, Acikel C, Oztas Y, Arpaci F, Topal T, Ozet A, Ataergin S, Kuzhan O, Oter S, Korkmaz A. Efficacy of melatonin, mercaptoethylguanidine and 1400W in doxorubicin- and trastuzumab-induced cardiotoxicity. J Pineal Res. 2011 Jan;50(1):89-96. doi: 10.1111/j.1600-079X.2010.00818.x. Epub 2010 Nov 9. PubMed PMID: 21062350.
5. Turk HM, Komurcu S, Arpaci F, Ozet A, Kilic S, Kuzhan O, Ozturk B, Yilmaz I, Ataergin S, Ozturk M. Factors affecting engraftment time in autologous peripheral stem cell transplantation. Asian Pac J Cancer Prev. 2010;11(3):697-702.PubMedPMID: 21039038.
6. Kanat O, Ozet A, Ataergin S, Arpaci F, Kuzhan O, Komurcu S, Ozturk B, Ozturk M. Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma. Med Princ Pract. 2010;19(5):344-7. doi: 10.1159/000316370. Epub 2010 Jul 14. PubMed PMID: 20639655.
7. Arpaci F, Safali M, Ozet A, Ural AU, Cetin T, Ozturk M, Ataergin S, Kuzhan O, Komurcu S, Ozturk B, Acikel C. The clinical significance of tumor cells in bone marrow or apheresis product and the efficacy of CD34+ selection and high-dose chemotherapy in patients with Stage III breast cancer. J Clin Apher. 2009;24(5):197-204. doi: 10.1002/jca.20211. PubMed PMID: 19816961.
8. Ozturk M, Komurcu S, Kilic S, Ozet A, Arpaci F, Ozturk B, Kuzhan O, Ataergin, S. Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. Support Care Cancer. 2009 Oct;17(10):1295-9. doi: 10.1007/s00520-009-0586-6. Epub 2009 Feb 6. PubMed PMID: 19198890.
9. Kuzhan, O., “Kanser Kaşeksisi”. Türkiye Klinikleri, Paraneoplastik sendromlar özel sayısı; Cilt 1, sayı:3,, s 90-95; 2008.
10. İnal, S., Taşçı, C., Karadurmuş, N., Kuzhan, O., Balkan, A., Özkan, M., Bilgiç, H., Özet, A., Ekiz, K., “The Association of D-Dimer Levels with Other Prognostic Factors in Patients with Lung Cancer, Türk J Med Sci, 2008:38(3):209-217.
11. Kuzhan, O., Ozet, A., Ulutin, C., Kurt , B., Komurcu, S., Ozturk, B., Ataergin, S., Gunhan, O., “Impact of c-erb2 status on survival after high dose chemotherapy in high-risk breast cancer patients” Saudi Med. J., Sep;28(9):477-482, (2007)
12. Kuzhan, O., Ozet, A., Ulutin, C., Komurcu, S., Arpaci, F., Ozturk, B., Ozturk, M., “Survival Benefit with GM-CSF use after high-dose chemotherapy in high-risk breast cancer”, Tumori, 93:550-556, (2007)
13. Arpaci, F., Tezcan, I., Kuzhan, O., Yalman, N., Uckan, D., Kurekci, AE., Ikinciogullari, A., Ozet, A., Tanyeli, A., “G-CSF-mobilized haploidentical peripheral blood stem cell transplantation in children with poor prognostic nonmalignant disorders”, Am. J. Hematol., Feb;83(2):133-136, (2007)
14. Ulutin, HC., Aksu, G., Fayda, M., Kuzhan, O., Tahmaz, L., Beyzadeoglu, M., “The value of postoperative radiotherapy in renal cell carcinoma: a single- institution experience”, Tumori, May-Jun;92(3):202-206, (2006)
15. Ulutin, HC, Fayda M., Aksu G., Cetinayak O., Kuzhan O., Ors F. “Primary glioblastoma multiforme in younger patients: a single -institution experience” Tumori, 92:407-411, 2006.
16. Acikel, CH., Kir, T., Komurcu, S., Kilic, S., Ozet, A., Rzayev, M., Arpaci, F., Ozturk, B., Ogur, R., Ataergin, S., Kuzhan, O., Hasde, M., “Some sociodemographic and diagnostic characteristics of military patients treated in the department of Medical Oncology”, Gulhane Military Medical Academy, Mil. Med., May;171(5):420-424, (2006)
17. Arpaci, F., Ataergin, S., Ozet, A., Erler, K., Basbozkurt, M., Ozcan, A., Komurcu, S., Ozturk, B., Celasun, B., Kilic, S., Kuzhan, O., “The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: results of a phase II study”, Cancer, Sep 1;104(5):1058- 1065, (2005)
18. Arpaci, F., Cetin, T., Ozet, A., Oysul, K., Pekel, A., Ataergin, S., Kuzhan, O., Komurcu, S., Ozturk, B., “The excessive numbers of total nucleated cells does not affect the performance of the CliniMACS”, Journal of Clinical Apheresis, 19:197-201, (2004)
19. Cetin, T., Arpaci, F., Ozet, A., Ozturk, B., Komurcu, S., Uzar, AI., Yilmaz, I., Beyzadeoglu, M., Oysul, K., Ataergin, S., Kuzhan, O., Pekel, A., “Stem cell mobilization by G-CSF in solid and hematological malignancies: Single 2 daily dose is beter than split dose in obese patients”, Journal of Clinical Apheresis, 18:120-124, (2003)
20. Comert, B., Mas, MR., Erdem, H., Dinc, A., Saglamkaya, U., Cigerim, M., Kuzhan, O., Unal, T., Kocabalkan, F., ”Insulin resistance in non-alcoholic steatohepatitis”, Digest Liver Dis., 33:353-8, (2001)
21. Mas, MR., Comert. B., Saglamkaya, U., Yamanel, L., Kuzhan, O., Ateşkan, U., Kocabalkan, F., “CA-125; a new marker for diagnosis and follow- up of patients with tuberculous peritonitis”, Digest Liver Dis., 32:595-7, (2000)
22. Turk HM, Komurcu S, Ozet A, Kuzhan O, Günhan O. An unusual presentation of extramedullary plasmacytoma in testis and review of the literature. Med Oncol. 2010 Dec;27(4):1378-80. doi: 10.1007/s12032-009- 9390-x. Epub 2009 Dec 25. PubMed PMID: 20035386.
23. Turk HM, Ozet A, Ozturk M, Komurcu S, Kuzhan O, Arpaci F, Ozturk B, Safali M. Isolated renal relapse of a case with non-Hodgkin”s lymphoma. Med Oncol. 2010 Jun;27(2):434-8. doi: 10.1007/s12032-009-9229-5. Epub 2009 May 13. PubMed PMID:19437146.
24. Turk HM, Ozet A, Kuzhan O, Komurcu F, Arpaci F, Ozturk B, Ataergin S. Paraneoplastic motor neuron disease resembling amyotrophic lateral sclerosis in a patient with renal cell carcinoma. Med Princ Pract. 2009;18(1):73-5. doi: 10.1159/000163053. Epub 2008 Dec 4. PubMed PMID: 19060497.
25. Özet, A., Uncu, D., Kuzhan, O., Öztürk, M., Günal, A., Kılıçlı, F., Arpacı, F.,”Metastatic Breast Cancer. Occurance After Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Case Report, Türkiye Klinikleri, J. Med Sci 2008;28: s758-760.
26. Kuzhan, O., Ulutin, HC., Arpaci, F., Ozet, A., Komurcu, S., Ozturk, B., “Cerebellar encephalopathy and acute psychosis associated with infusion of 2 DMSO preserved stem cells”, Neurology Psychiatry and Brain Research, 14:65-66, (2007)
27. Kanat, O., Ozet, A., Ataergin, S., Kuzhan, O., Arpaci, F., Ozturk, B., Komurcu, S., Ozturk, M., “Bisphosphonate treatment as a cause of jaw osteonecrosis”, Oral Dis., 13(3):346-347, (2007)
28. Ulutin, C., Kuzhan, O.,” Target volume of postoperative radiotherapy of pancreatic cancer” Tumori, May-Jun;92(3):270, (2006)
29. Kanat, O., Ozet, A., Ataergin, S., Arpaci, F., Ozturk, B., Ozturk, M., Komurcu, S., Kuzhan, O., “A case of advanced scalp angiosarcoma successfully treated with combination chemotherapy of adriamycin, cisplatin and ifosfamide”, Clinical Oncology, June;18(5):426-427, (2006)
30. Karacalioglu, O., Ilgan, S., Kuzhan, O., Emer, O., Ozguven, M., “Disseminated metastatic disease of osteosarcoma of the femur in the abdomen: unusual metastatic pattern on Tc-99m MDP bone scan”, Annals of Nuclear Medicine, Jul;20(6):437-440 (2006)
31. Ulutin, C., Ozturk, B., Onguru, O., Kuzhan, O., Arpaci, F., Ozet, A., “Treatment of primary cutaneous B-cell lymphoma with radiotherapy”, Radiation Medicine, 23 (4) 292-295 p.p., (2005)
1. Alan O, Kuzhan O, Koca S, Telli TA, Basoglu T, Ercelep O, Filinte D, Sengul Y, Arikan H, Kaya S, Babacan NA, Dane F, Yumuk PF. How long should we continuecrizotinib in ALK translocation-positive inflammatory myofibroblastic tumors?Long-term complete response with crizotinib and review of the literature. JOncol Pharm Pract. 2020 Jun;26(4):1011-1018. doi: 10.1177/1078155219879757. Epub 2019 Oct 15. PMID: 31615346.
